Radioembolisation vs sorafenib monotherapy
Non‐serious adverse events (hand‐foot skin reaction) · people with hepatocellular carcinoma
Radioembolisation may leads to lower non‐serious adverse events (hand‐foot skin reaction) compared with sorafenib (low certainty).
1 finding from 1 review
- Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma 2020 · Cochrane Headline outcomes onlyRR 0.02 [0, 0.06]2 studies · 734 participantsLow